127 completed, 33 unknown, 17 terminated, 11 recruiting. 33 Phase 3, 27 Phase 2, 25 Phase 4, 20 Not applicable, 12 Phase 1.
Follow Acromegaly: new trials by email Literature Review of Acromegaly trials Research Report on Acromegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hypoproteic Diet in Acromegaly Usual clinical practice + hypoproteic diet - Acromegaly | Not applicable | Suspended | Azienda Ospedaliero Universitaria Maggiore della Carita | 12 | 2026-12-01 | 2026-10-29 |
| PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease | Phase 3 | Not yet recruiting | University College, London | 82 | 2026-09-01 | 2026-10-01 |
| A Study to Evaluate MAR002 for Acromegaly MAR002, Placebo - Acromegaly | Phase 2 | Recruiting | Marea Therapeutics | 72 | 2026-07-23 | 2026-09-11 |
| Direct Versus Video Laryngoscopy in Patients With Acromegaly Acromegaly, Nonfunctioning Pituitary Adenoma | Not yet recruiting | Muzaffer GENCER | 40 | 2026-07-01 | 2026-06-22 | |
| A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) T25-Fast, Mycapssa, T25-Fed - Acromegaly | Phase 1 | Completed | Triastek (Shanghai) Limited | 18 | 2026-06-25 | 2026-09-16 |
| An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly Octreotide subcutaneous depot - Acromegaly | Recruiting | Camurus AB | 200 | 2026-06-05 | 2026-10-27 | |
| A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers NTQ6179, NTQ6179 placebo - Acromegaly | Phase 1 | Recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 56 | 2026-04-23 | 2026-11-03 |
| Ultrasound in Predicting Difficult Intubation in Acromegaly Patients observational study - Acromegaly Due to Pituitary Adenoma, Difficult Intubation | Not yet recruiting | Başakşehir Çam & Sakura City Hospital | 34 | 2025-12-25 | 2025-12-29 | |
| A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs Debio 4126, Placebo - Acromegaly | Phase 3 | Recruiting | Debiopharm International SA | 119 | 2025-11-26 | 2026-10-23 |
| ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly ALXN2420, Placebo - Acromegaly | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2025-10-28 | 2026-08-07 |
| Effects of Pasireotide Lar Therapy on Bone Metabolism morphometric spine radiography - Acromegaly Due to Pituitary Adenoma, Acromegaly | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 120 | 2025-09-08 | 2025-09-18 | |
| Study of MAR002 in Healthy Men MAR002, Placebo - Acromegaly | Phase 1 | Recruiting | Marea Therapeutics | 45 | 2025-08-11 | 2026-01-12 |
| Diet in the Management of Acromegaly Diet - Acromegaly | Not applicable | Unknown | Cedars-Sinai Medical Center | 9 | 2024-09-20 | 2024-04-19 |
| Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models Endocrine Disorders, Adiposity | Not yet recruiting | IRCCS San Raffaele | 200 | 2024-07-01 | 2024-06-11 | |
| Ketogenic vs. Mediterranean Diet on Metabolic and Hormonal Parameters in Patients With Active Acromegaly Ketogenic diet, Mediterranean diet - Acromegaly | Not applicable | Completed | University of Palermo | 26 | 2024-06-30 | 2025-09-05 |
| A Phase 1 Study of TE-8214 Solution in Healthy Volunteers TE-8214 - SAD, Placebo - Acromegaly | Phase 1 | Completed | Immunwork, Inc. | 32 | 2024-06-18 | 2025-05-20 |
| A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly | Completed | Ipsen | 20 | 2024-05-29 | 2024-12-24 | |
| A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly SYHX2008, Sandostatin LAR - Acromegaly | Phase 2 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 78 | 2024-04-16 | 2026-09-11 |
| The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly Acromegaly | Unknown | IRCCS San Raffaele | 100 | 2023-11-24 | 2024-09-19 | |
| Acromegaly: Balance, Falls and Fracture Risk HR-pQCT, DXA scan, Bone microindentation - Acromegaly | Completed | Christian Alexander H Rosendal | 34 | 2023-06-02 | 2024-05-16 |
Showing 20 of 201. Sign in to see all of them.
Pituitary Neoplasms (23) · Pituitary Diseases (9) · Dwarfism, Pituitary (6) · Gigantism (6) · Insulin Resistance (6) · Pituitary ACTH Hypersecretion (6) · Prolactinoma (6) · Growth Hormone-Secreting Pituitary Adenoma (4) · Adenoma (3) · Cushing Syndrome (3) · Endocrine System Diseases (3) · Hypertrophy, Left Ventricular (3) · Neoplasms (3) · Neuroendocrine Tumors (3)
Bone Diseases, Endocrine (201) · Brain Diseases (201) · Central Nervous System Diseases (201) · Hyperpituitarism (201) · Hypothalamic Diseases (201) · Musculoskeletal Diseases (201) · Nervous System Diseases (201) · Bone Diseases (199) · Endocrine System Diseases (198) · Pituitary Diseases (192) · Neoplasms (28) · Endocrine Gland Neoplasms (26) · Neoplasms by Site (26) · Central Nervous System Neoplasms (23) · Hypothalamic Neoplasms (23)
Octreotide (29) · lanreotide (21) · pegvisomant (18) · pasireotide (10) · Glucose Tolerance Test (5) · Cabergoline (4) · Injections (3) · Somatostatin (3) · Absorptiometry, Photon (2) · Blood Specimen Collection (2) · Duration of Therapy (2) · Growth Hormone (2) · Human Growth Hormone (2) · Magnetic Resonance Spectroscopy (2) · PTR 3173 (2)
Ipsen (34) · Novartis Pharmaceuticals (15) · Cedars-Sinai Medical Center (10) · University of Aarhus (9) · Pfizer (7) · Crinetics Pharmaceuticals Inc. (5) · Federico II University (5) · Camurus AB (4) · Columbia University (4) · Massachusetts General Hospital (4) · Ambrilia Biopharma, Inc. (3) · Assistance Publique - Hôpitaux de Paris (3) · Chiasma, Inc. (3) · Copenhagen University Hospital, Rigshospitalet (3) · Endo USA Inc., a Keenova Therapeutics Company (3)
United States (64) · Italy (45) · France (37) · Germany (34) · United Kingdom (31) · Poland (27) · Hungary (25) · Denmark (23) · Spain (22) · Brazil (21) · Romania (18) · Serbia (18) · Netherlands (17) · Belgium (16) · Russia (16)
Annamaria Colao, MD (3) · Raphael Naudin, M.D. (3) · Shlomo Melmed, MD (3) · John Carmichael, MD (2) · Karen Miller, MD (2) · Marta Korbonits, MD PhD (2) · Odelia Cooper, MD (2) · Pamela U Freda, MD (2) · Sabrina Chiloiro (2) · Ulla Feldt-Rasmussen, Professor (2)
PMID 17259801, PMID 17984237, PMID 10690849, PMID 12641619, PMID 14769829, PMID 15613435, PMID 15827109, PMID 16449332, PMID 16487447, PMID 16537687, PMID 18445662, PMID 34173129, PMID 36792844, PMID 40418492, PMID 41701620, PMID 9808008, PMID 10469005, PMID 10753124, PMID 10792333, PMID 10999798, PMID 11397887, PMID 11788630, PMID 12843148, PMID 14764779, PMID 15070920, PMID 15080776, PMID 15080778, PMID 15099442, PMID 15272916, PMID 15362960, PMID 15531475, PMID 15649100, PMID 15817912, PMID 15886238, PMID 15886256, PMID 16181243, PMID 16322377, PMID 16373932, PMID 16584510, PMID 16918950, PMID 17167139, PMID 17171126, PMID 17311860, PMID 17465997, PMID 17555511, PMID 17892497, PMID 18248639, PMID 18381583, PMID 18492760, PMID 18593770
2019 (4), 2004 (3), 2014 (3), 2015 (3), 2005 (2), 2018 (2), 2009 (1), 2017 (1), R56DK064720 (1)